{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Evolent Health, Inc.
Evolent Health Stock Plummets to New 52-Week Low at $4.92
Evolent Health, Inc. has hit a new 52-week low, trading at USD 4.92, reflecting a significant decline over the past year. The company has reported negative financial results for three consecutive quarters, with substantial losses in profit and operating cash flow, indicating ongoing financial challenges.
Evolent Health Hits New 52-Week Low at $5.97 Amidst Major Decline
Evolent Health, Inc. has hit a new 52-week low, trading at USD 5.97, reflecting a 74.7% decline over the past year. The company has reported negative financial results for three consecutive quarters, with significant losses in profit and cash flow, raising concerns about its market position and future viability.
Evolent Health Stock Plummets to New 52-Week Low of $6.49
Evolent Health, Inc. has hit a new 52-week low, trading at USD 6.49, reflecting a significant decline over the past year. The company has reported negative financial results for three consecutive quarters, with substantial losses in profit and cash flow, indicating ongoing financial challenges and underperformance in the market.
Evolent Health Stock Plummets to New 52-Week Low at $6.50
Evolent Health, Inc. has hit a new 52-week low, trading at USD 6.50, reflecting a 71.67% decline over the past year. The company has reported negative financial results for three consecutive quarters, with significant losses in both pre-tax and net profits, indicating ongoing financial challenges.
Evolent Health Stock Plummets to New 52-Week Low of $6.53
Evolent Health, Inc. has hit a new 52-week low, reflecting a significant decline in its stock price over the past year. The company has faced ongoing financial difficulties, including negative returns and consecutive quarterly losses, while its market capitalization stands at USD 1,151 million with no dividend yield.
Evolent Health Stock Plummets to New 52-Week Low of $6.58
Evolent Health, Inc. has hit a new 52-week low, trading at USD 6.58, reflecting a significant decline over the past year. The company faces ongoing financial challenges, including negative quarterly results, a market capitalization of USD 1,151 million, and a concerning return on equity of -10.28%.
Evolent Health Stock Hits Day Low of $8.91 Amid Price Pressure
Evolent Health, Inc. faced a notable decline in stock value, contrasting with the S&P 500's modest drop. Despite a slight recovery over the past week, the company's longer-term performance is troubling, marked by significant annual losses and ongoing profitability challenges, including negative results for three consecutive quarters.
Evolent Health Stock Soars 14.54% to Day High of $9.63
Evolent Health, Inc. saw a notable increase today, contrasting with a decline in the S&P 500. Despite a recent weekly gain, the company faces significant long-term challenges, including a substantial yearly decline and low profitability metrics. Its market capitalization is categorized as small-cap, currently at USD 1,151 million.
Is Evolent Health, Inc. technically bullish or bearish?
As of September 10, 2025, Evolent Health, Inc. has shifted to a mildly bearish trend, indicated by bearish signals from moving averages and Bollinger Bands, despite a conflicting mildly bullish MACD on the weekly; the stock has underperformed the S&P 500 significantly, with a year-to-date return of -22.31% compared to the S&P 500's 12.22%.
Is Evolent Health, Inc. overvalued or undervalued?
As of August 4, 2016, Evolent Health, Inc. is considered overvalued with a risky valuation grade, reflected by its high Price to Book Value of 1.06, EV to EBITDA ratio of 15.47, negative ROE of -8.76%, and significant underperformance against the S&P 500, with year-to-date and one-year returns of -22.31% and -71.66%, respectively.
Is Evolent Health, Inc. overvalued or undervalued?
As of August 4, 2016, Evolent Health, Inc. is considered overvalued with a negative P/E ratio and poor return metrics, contrasting with its peers Grand Canyon Education and MAXIMUS, and has experienced a significant stock decline of -53.33% over the past year.
Is Evolent Health, Inc. technically bullish or bearish?
As of June 2, 2025, the trend is mildly bearish due to daily moving averages and monthly MACD indicating bearish momentum, despite some short-term bullish signals from the weekly MACD and KST.
Who are in the management team of Evolent Health, Inc.?
As of March 2022, Evolent Health, Inc.'s management team includes Executive Chairman and Co-Founder Frank Williams, CEO and Co-Founder Seth Blackley, and Lead Independent Director Cheryl Scott, along with Board members David Farner, Diane Holder, Kim Keck, and Independent Director Craig Barbarosh.
What does Evolent Health, Inc. do?
Evolent Health, Inc. supports healthcare systems and physician organizations in transitioning to value-based care, with recent net sales of $484 million and a net loss of $65 million. The company has a market capitalization of approximately $1 billion.
How big is Evolent Health, Inc.?
As of Jun 18, Evolent Health, Inc. has a market capitalization of 1,009.78 million, with net sales of 2,398.73 million and a net profit of -108.96 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
